The pandemic continues to cause unprecedented disruption across industries worldwide.
Get detailed insights regarding the impact of COVID-19 on the market.
The global human enhancement market size reached US$ 84.6 Billion in 2021. Looking forward, IMARC Group expects the market to reach US$ 190.2 Billion by 2027, exhibiting a growth rate (CAGR) of 14.4% during 2022-2027. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic. These insights are included in the report as a major market contributor.
Human enhancement refers to a natural, artificial, and technological alteration of the body to enhance cognitive and physical capabilities and functions of individuals. It is undertaken using drugs, hormones, implants, genetic engineering to dietary supplements and cosmetic surgeries for self-improvement. Nowadays, advances in human enhancement technologies provide resistance against diseases like malaria, tuberculosis, and Lyme. They also allow up-to-date diagnostic and advancements in genome editing technologies, such as clustered regularly interspaced short palindromic repeats (CRISPR) for a functional cure of human immunodeficiency virus (HIV) infection.
The growing prevalence of acute and chronic diseases, in confluence with the increasing access to healthcare services, represents one of the key factors positively influencing the demand for human enhancement technologies around the world. These technologies mainly include nanotechnology, information technology (IT), and cognitive science, which assist in upgrading biomedical interventions as well as diagnose and treat various diseases. They also comprise active control systems that help create limb prosthetics with characteristics that exceed human performance. Moreover, emerging technologies like genetic engineering, neuronal implants, brain-computer interfaces, and three-dimensional (3D) bioprinting are contributing to the market growth. Apart from this, due to rising geopolitical tension between countries, security agencies of several countries are investing in research programs to improve battlefield performance. For instance, the ethics committee in the French Army approved the research of human enhancement technologies for developing enhanced soldiers. This research also involves the utilization of advanced systems, ranging from drugs to exoskeletons, to enhance military personnel in targeting decisions. These factors are anticipated to drive the adoption of human enhancement technologies and influence the market positively in the coming years.
IMARC Group provides an analysis of the key trends in each sub-segment of the global human enhancement market report, along with forecasts at the global, regional and country level from 2022-2027. Our report has categorized the market based on product, device type and end user.
Breakup by Product:
Breakup by Device Type:
Breakup by End User:
Breakup by Region:
The competitive landscape of the industry has also been examined along with the profiles of the key players being BrainGate, B-Temia Inc, Ekso Bionics, Google LLC, Magic Leap Inc, Raytheon Technologies Corporation, ReWalk Robotics Ltd, Samsung Electronics Co. Ltd., Second Sight Medical Products Inc. and Vuzix Corporation.
|Base Year of the Analysis||2021|
|Segment Coverage||Product, Device Type, End User, Region|
|Region Covered||Asia Pacific, Europe, North America, Latin America, Middle East and Africa|
|Countries Covered||United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico|
|Companies Covered||BrainGate, B-Temia Inc, Ekso Bionics, Google LLC, Magic Leap Inc, Raytheon Technologies Corporation, ReWalk Robotics Ltd, Samsung Electronics Co. Ltd., Second Sight Medical Products Inc. and Vuzix Corporation|
|Customization Scope||10% Free Customization|
|Report Price and Purchase Option||Single User License: US$ 2499
Five User License: US$ 3499
Corporate License: US$ 4499
|Post-Sale Analyst Support||10-12 Weeks|
|Delivery Format||PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)|
The global human enhancement market was valued at US$ 84.6 Billion in 2021.
We expect the global human enhancement market to exhibit a CAGR of 14.4% during 2022-2027.
The sudden outbreak of the COVID-19 pandemic had led to postponement of elective cosmetic surgeries and treatment for malaria, tuberculosis, and Lyme to reduce the risk of the coronavirus infection upon hospital visits and interaction with medical equipment, thereby negatively impacting the global market for human enhancement technology.
The growing prevalence of acute and chronic diseases, along with the increasing demand for human enhancement technologies to assist in upgrading biomedical interventions as well as diagnose and treat various diseases, is primarily driving the global human enhancement market.
Based on the product, the global human enhancement market can be categorized into exoskeleton, smart devices, medical devices, implants, and others. Currently, smart devices account for the majority of the global market share.
Based on the device type, the global human enhancement market has been segregated into body worn and non-body worn, where body worn devices currently hold the largest market share.
Based on the end user, the global human enhancement market can be bifurcated into healthcare, defense, information technology, and others. Among these, the healthcare sector exhibits a clear dominance in the market.
On a regional level, the market has been classified into North America, Asia Pacific, Europe, Latin America, and Middle East and Africa, where North America currently dominates the global market.
Some of the major players in the global human enhancement market include BrainGate, B-Temia Inc, Ekso Bionics, Google LLC, Magic Leap Inc, Raytheon Technologies Corporation, ReWalk Robotics Ltd, Samsung Electronics Co. Ltd., Second Sight Medical Products Inc., and Vuzix Corporation.
REACH OUT TO US
Call us on
( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )
Drop us an email at